Is oxidized low-density lipoprotein present in vivo?
Basic research has provided strong evidence that oxidation of LDL plays an important role in the pathogenesis of atherosclerosis. Several mechanisms have been identified which can lead to LDL oxidation in vivo. Clinical and epidemiological studies have provided circumstantial evidence that oxidized LDL, as measured by serum autoantibody levels, may be associated with the progression of atherosclerotic vascular disease. This review discusses recent findings regarding the presence of oxidized LDL (ox-LDL) in vivo and the significance of ox-LDL autoantibody measurements as a tool to predict cardiovascular diseases in various patient populations.
Ylä-Herttuala
S
S
A.I. Virtanen Institute of Molecular Sciences, Kuopio, Finland. ylahertt@keula.uku.fi
D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology / Q000378:metabolism*; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology
D001323:Autoantibodies; D015415:Biomarkers; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein